Lima Viviane D, Wang Lu, Brumme Chanson, Wu Lang, Montaner Julio S G, Harrigan P Richard
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Division of AIDS, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
PLoS One. 2017 Feb 2;12(2):e0171155. doi: 10.1371/journal.pone.0171155. eCollection 2017.
Plasma HIV-1 RNA levels (pVLs), routinely used for clinical management, are influenced by measurement error (ME) due to physiologic and assay variation.
To assess the ME of the COBAS HIV-1 Ampliprep AMPLICOR MONITOR ultrasensitive assay version 1.5 and the COBAS Ampliprep Taqman HIV-1 assay versions 1.0 and 2.0 close to their lower limit of detection. Secondly to examine whether there was any evidence that pVL measurements closest to the lower limit of quantification, where clinical decisions are made, were susceptible to a higher degree of random noise than the remaining range.
We analysed longitudinal pVL of treatment-naïve patients from British Columbia, Canada, during their first six months on treatment, for time periods when each assay was uniquely available: Period 1 (Amplicor): 08/03/2000-01/02/2008; Period 2 (Taqman v1.0): 07/01/2010-07/03/2012; Period 3 (Taqman v2.0): 08/03/2012-30/06/2014. ME was estimated via generalized additive mixed effects models, adjusting for several clinical and demographic variables and follow-up time.
The ME associated with each assay was approximately 0.5 log10 copies/mL. The number of pVL measurements, at a given pVL value, was not randomly distributed; values ≤250 copies/mL were strongly systematically overrepresented in all assays, with the prevalence decreasing monotonically as the pVL increased. Model residuals for pVL ≤250 copies/mL were approximately three times higher than that for the higher range, and pVL measurements in this range could not be modelled effectively due to considerable random noise of the data.
Although the ME was stable across assays, there is substantial increase in random noise in measuring pVL close to the lower level of detection. These findings have important clinical significance, especially in the range where key clinical decisions are made. Thus, pVL values ≤250 copies/mL should not be taken as the "truth" and repeat pVL measurement is encouraged to confirm viral suppression.
常用于临床管理的血浆HIV-1 RNA水平(pVLs)受生理和检测变异导致的测量误差(ME)影响。
评估COBAS HIV-1 Ampliprep AMPLICOR MONITOR超灵敏检测法1.5版以及COBAS Ampliprep Taqman HIV-1检测法1.0版和2.0版在接近其检测下限处的测量误差。其次,检验是否有证据表明在做出临床决策时,最接近定量下限的pVL测量值比其余范围更容易受到更高程度的随机噪声影响。
我们分析了加拿大不列颠哥伦比亚省初治患者在治疗的前六个月的纵向pVL,分析每种检测法单独可用的时间段:第1阶段(Amplicor):2000年3月8日至2008年2月1日;第2阶段(Taqman v1.0):2010年1月7日至2012年3月7日;第3阶段(Taqman v2.0):2012年3月8日至2014年6月30日。通过广义相加混合效应模型估计测量误差,并对多个临床和人口统计学变量以及随访时间进行调整。
与每种检测法相关的测量误差约为0.5 log10拷贝/毫升。在给定的pVL值下,pVL测量值的数量并非随机分布;在所有检测法中,pVL值≤250拷贝/毫升的情况系统性地大量超出现象,随着pVL升高,其发生率单调下降。pVL≤250拷贝/毫升时的模型残差比更高范围时大约高三倍,并且由于数据存在相当大的随机噪声,该范围内的pVL测量值无法有效建模。
尽管各检测法的测量误差稳定,但在测量接近检测下限的pVL时,随机噪声大幅增加。这些发现具有重要的临床意义,尤其是在做出关键临床决策的范围内。因此,不应将pVL值≤250拷贝/毫升视为“真实值”,鼓励重复进行pVL测量以确认病毒抑制情况。